Ionis Pharma EVP Geary sells $503,671 in IONS stock

Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (NASDAQ:IONS), Richard S. Geary, sold 10,000 shares of the company’s common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $50.3671, for a total value of $503,671. The prices for the transactions ranged from $50.01 to $50.92. The stock, currently trading at $59.35 with a market capitalization of $9.47 billion, has seen remarkable gains of 39.2% in the past week and 75.85% over six months. According to InvestingPro analysis, the stock appears overvalued at current levels, with technical indicators suggesting overbought conditions.

Following the transaction, Geary directly owns 79,657 shares of Ionis Pharmaceuticals.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 6, 2025.

In other recent news, Ionis Pharmaceuticals has reported positive results from its Phase 3 CORE and CORE2 trials, demonstrating significant benefits in triglyceride lowering and reducing the risk of acute pancreatitis. These results have led to several analyst firms adjusting their outlooks on the company. RBC Capital raised its price target for Ionis Pharmaceuticals to $80, maintaining an Outperform rating, following promising data from the trials. H.C. Wainwright also increased its price target to $95, citing strong triglyceride reductions in pivotal studies. Additionally, BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, highlighting the potential of Olezarsen to become a blockbuster drug in the U.S. market. Oppenheimer joined in by raising its price target to $81, maintaining an Outperform rating due to the positive trial results for Tryngolza (olezarsen) in treating severe hypertriglyceridemia. These developments reflect a growing confidence among analysts in Ionis Pharmaceuticals’ future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.